Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction.
No risks detected for VTFN from our risk checks.
Flawless balance sheet with solid track record.
Share Price & News
How has Vitrolife's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: VTFN has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: VTFN underperformed the German Biotechs industry which returned 6.8% over the past year.
Return vs Market: VTFN underperformed the German Market which returned 15.1% over the past year.
Price Volatility Vs. Market
How volatile is Vitrolife's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Vitrolife undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: VTFN (€17.04) is trading above our estimate of fair value (€6.39)
Significantly Below Fair Value: VTFN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: VTFN is poor value based on its PE Ratio (52.3x) compared to the Biotechs industry average (42.9x).
PE vs Market: VTFN is poor value based on its PE Ratio (52.3x) compared to the German market (20.9x).
Price to Earnings Growth Ratio
PEG Ratio: VTFN is poor value based on its PEG Ratio (4.7x)
Price to Book Ratio
PB vs Industry: VTFN is overvalued based on its PB Ratio (11.2x) compared to the DE Biotechs industry average (3.5x).
How is Vitrolife forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VTFN's forecast earnings growth (11.2% per year) is above the savings rate (-0.4%).
Earnings vs Market: VTFN's earnings (11.2% per year) are forecast to grow slower than the German market (13.3% per year).
High Growth Earnings: VTFN's earnings are forecast to grow, but not significantly.
Revenue vs Market: VTFN's revenue (10.4% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: VTFN's revenue (10.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VTFN's Return on Equity is forecast to be low in 3 years time (20%).
How has Vitrolife performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VTFN has high quality earnings.
Growing Profit Margin: VTFN's current net profit margins (25.9%) are lower than last year (26.9%).
Past Earnings Growth Analysis
Earnings Trend: VTFN's earnings have grown significantly by 21.5% per year over the past 5 years.
Accelerating Growth: VTFN's earnings growth over the past year (23.6%) exceeds its 5-year average (21.5% per year).
Earnings vs Industry: VTFN earnings growth over the past year (23.6%) exceeded the Biotechs industry -4.7%.
Return on Equity
High ROE: VTFN's Return on Equity (21.4%) is considered high.
Return on Assets
Return on Capital Employed
How is Vitrolife's financial position?
Financial Position Analysis
Short Term Liabilities: VTFN's short term assets (SEK1.2B) exceed its short term liabilities (SEK202.4M).
Long Term Liabilities: VTFN's short term assets (SEK1.2B) exceed its long term liabilities (SEK138.7M).
Debt to Equity History and Analysis
Debt Level: VTFN is debt free.
Reducing Debt: VTFN has no debt compared to 5 years ago when its debt to equity ratio was 12.2%.
Debt Coverage: VTFN has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: VTFN has no debt, therefore coverage of interest payments is not a concern.
Inventory Level: VTFN has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if VTFN's debt is covered by short term assets.
What is Vitrolife's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Purchase Vitrolife before the 'Buy Limit' to receive their next dividend payment.
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: VTFN's dividend (0.57%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.31%).
High Dividend: VTFN's dividend (0.57%) is low compared to the top 25% of dividend payers in the German market (3.59%).
Stability and Growth of Payments
Stable Dividend: VTFN is not paying a notable dividend for the German market, therefore no need to check if payments are stable.
Growing Dividend: VTFN is not paying a notable dividend for the German market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: VTFN is not paying a notable dividend for the German market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VTFN's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Thomas Axelsson (60yo)
Mr. Thomas Axelsson, M.Sc. employed at Vitrolife AB (publ) in 2011 and has been its Chief Executive Officer of since April 18, 2012. Mr. Axelsson served as an Acting Chief Executive Officer of Vitrolife fr ...
CEO Compensation Analysis
Compensation vs Market: Thomas's total compensation ($USD0.00) is below average for companies of similar size in the German market ($USD1.49M).
Compensation vs Earnings: Thomas's compensation has been consistent with company performance over the past year.
|Chief Executive Officer||7.8yrs||no data||0.080% SEK1.5m|
|CFO & Investor Relations||0yrs||no data||0.019% SEK350.2k|
|Chief Operating Officer||2.4yrs||no data||0.0080% SEK145.8k|
|Vice President of Technology||0yrs||no data||no data|
|Chief Scientific Officer||2.5yrs||no data||0.0021% SEK39.2k|
|Chief Sales & Marketing Officer||2.4yrs||no data||0.0069% SEK126.4k|
|Director of Human Resources||12yrs||no data||no data|
|Senior Vice President of New Business & Strategic Development||1.4yrs||kr100.00k||0.043% SEK795.8k|
|Business Unit Director of Media||2.4yrs||no data||0.011% SEK197.8k|
|Head Auditor||0yrs||no data||no data|
Experienced Management: VTFN's management team is considered experienced (2.4 years average tenure).
|Independent Director||0.8yrs||no data||no data|
|Chairman||0.8yrs||no data||0.028% SEK512.4k|
|Independent Director||2.1yrs||no data||no data|
|Independent Director||6.8yrs||no data||0.0046% SEK84.3k|
Experienced Board: VTFN's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: VTFN insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Vitrolife AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Vitrolife AB (publ)
- Ticker: VTFN
- Exchange: DB
- Founded: 1981
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr19.409b
- Listing Market Cap: kr1.830b
- Shares outstanding: 108.55m
- Website: https://www.vitrolife.com
Number of Employees
- Vitrolife AB (publ)
- Gustaf Werners gata 2
- Västra Frölunda
- 421 32
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|VITR||OM (OMX Nordic Exchange Stockholm)||Yes||Common Shares||SE||SEK||Jun 2001|
|VTFN||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Jun 2001|
|0YAY||LSE (London Stock Exchange)||Yes||Common Shares||GB||SEK||Jun 2001|
|VITRS||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Common Shares||GB||SEK||Jun 2001|
|VTRL.Y||OTCPK (Pink Sheets LLC)||UNSPONSORED ADR||US||USD||May 2016|
Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It offers oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; cryopreservation; and preimplantation genetic testing products. The company also provides EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors; and pH online. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1981 and is headquartered in Gothenburg, Sweden.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/20 21:12|
|End of Day Share Price||2020/02/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.